delivered to the knee extensors during and 2 s post the MVC (). Within 2.5 min post-exercise, neuromuscular function measures were repeated and then a final blood sample was obtained. Figure 2. Sprint time (A) and blood lactate (B) during the repeated sprint protocol. * = P < 0.05 vs. sprint 1 (panel A) or pre (panel B). Values are means ± SD for 12 participants. Pre Post Global fatigue Figure 3. Maximal MVC (N) 604 ± 77 529 ± 73* voluntary contraction Peripheral fatigue (A), potentiated Qtw,pot (N) 212 ± 39 162 ± 29* twitch force ERT (N) 188 ± 60 138 ± 57* (B) and voluntary MRFD (N∙s-1) 7600 ± 2217 5984 ± 1303* activation (C) for the CT (ms) 78 ± 13 66 ± 11* knee extensors during the control trial. These MRR (N∙s-1) ± 650 ± 562 −2094 −1826 data emphasise the RT0.5 (ms) 80 ± 9 66 ± 11* consistent nature of Central fatigue such measures during a Motor point VA 93 ± 4 85 ± 10* controlled setting. Data VATMS 96 ± 3 87 ± 8* are means ± SE for 9 participants. Figure 4. Maximum voluntary contraction (A), potentiated knee extensor twitch force (B) and motor point voluntary activation (VA; open bars, panel c) pre, during and immediately post the repeated sprint protocol. Data for voluntary activation measured using TMS (VATMS; closed bars, panel c) is shown pre and immediately post the repeated sprint protocol. * = P < 0.05 vs. the pre-exercise value. Values are means ± SEM for 12 participants. Table 1. Neuromuscular function pre- and post-repeated sprint activity. Values are means ± SD for 12 participants.
delivered to the knee extensors during and 2 s post the MVC (). Within 2.5 min post-exercise, neuromuscular function measures were repeated and then a final blood sample was obtained. Figure 2. Sprint time (A) and blood lactate (B) during the repeated sprint protocol. * = P < 0.05 vs. sprint 1 (panel A) or pre (panel B). Values are means ± SD for 12 participants. Figure 3. Maximal voluntary contraction (A), potentiated twitch force (B) and voluntary activation (C) for the knee extensors during the control trial. These data emphasise the consistent nature of such measures during a controlled setting. Data are means ± SE for 9 participants. Figure 4. Maximum voluntary contraction (A), potentiated knee extensor twitch force (B) and motor point voluntary activation (VA; open bars, panel c) pre, during and immediately post the repeated sprint protocol. Data for voluntary activation measured using TMS (VATMS; closed bars, panel c) is shown pre and immediately post the repeated sprint protocol. * = P < 0.05 vs. the pre-exercise value. Values are means ± SEM for 12 participants. Table 1. Neuromuscular function pre- and post-repeated sprint activity. Values are means ± SD for 12 participants. Pre Post Global fatigue MVC (N) 604 ± 77 529 ± 73* Peripheral fatigue Qtw,pot (N) 212 ± 39 162 ± 29* ERT (N) 188 ± 60 138 ± 57* MRFD (N∙s-1) 7600 ± 2217 5984 ± 1303* CT (ms) 78 ± 13 66 ± 11* MRR (N∙s-1) −2094 ± 650 −1826 ± 562 RT0.5 (ms) 80 ± 9 66 ± 11* Central fatigue Motor point VA 93 ± 4 85 ± 10* VATMS 96 ± 3 87 ± 8*
Text_-_Clean.docx